Company Overview of Virobay Inc.
Virobay, Inc., a clinical-stage pharmaceutical company, develops and commercializes drugs for the treatment of neuropathic pain, autoimmune diseases, and fibrosis. The company is developing VBY-036, a cathepsin S inhibitor, which has completed Phase I clinical trials for the treatment of neuropathic pain and crohn’s disease; and VBY-891, a cathepsin S inhibitor that has completed Phase I clinical trials for the treatment of psoriasis. It is also developing VBY-376, a cathepsin B inhibitor, which has completed a Phase I clinical trial to treat liver fibrosis in patients with nonalcoholic steatohepatitis; and VBY-825, an inhibitor of multiple cathepsins that is in preclinical studies for treat...
1360 Willow Road
Menlo Park, CA 94025
Founded in 2006
Key Executives for Virobay Inc.
Co-Founder, Chairman, Chief Executive Officer, President and Secretary
Co-Founder, Director, Chairperson of Nominating & Corporate Governance Committee and Member of Audit Committee
Senior Vice President of Project Management and Operations
Head of Clinical Operations and Clinical Trial Manager of Clinical Operations
Vice President of Chemistry, Manufacturing and Controls
Compensation as of Fiscal Year 2015.
Virobay Inc. Key Developments
Virobay Appoints James Welch as Chief Financial Officer
Jun 25 14
Virobay Inc. announced the appointment of James Welch as Chief Financial Officer, effective as of June 20, 2014. Prior to joining Virobay, Mr. Welch was Chief Financial Officer at AcelRx Pharmaceuticals.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries